IGF1 and prostate carcinoma: Chromosomal rearrangements leading to oncogenic fusion like TMPRSS2-ERG, EWS-WT1, and PAX3-FKHR, sustain IGF1R expression in prostate cancer, desmoplastic small cell tumor and alveolar rhabdomyosarcoma, respectively [69,70,71,72], while EWS-FLI favors IGF1 but inhibits IGFBP3 transcription in Ewing sarcoma [73].